Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research
Benefits of Pioglitazone Plus Insulin For Type 2
How Diabetes Increases Asthma Exacerbations
Why Monthly Lifestyle Counseling For Patients with Diabetes?
MOST POPULAR ARTICLES OF THE MONTH
#1 Updated Consensus Report on Diabetic Nutrition Therapy
#2 What Causes Blood Glucose to Go Down or Up During Exercise
Editor's Note
It has been a dozen years since Dr. Steven Nissen took direct aim at pioglitazone and rosiglitazone, based on his interpretation of cardiac risk factors. The FDA rushed to put severe restriction on their usage and finally in 2010 rosiglitazone, also known as Avandia, was withdrawn from the market. Pioglitazone was still prescribed, but a once blockbuster drug was reduced to a small market share.
Fast forward the clock a couple of years and the FDA almost totally reverses its opinion and in an “oops” moment admits that they overreacted.
Now it is 2019 and our intern Taylor-Eugene Simmons, Florida A&M University, College of Pharmacy & Pharmaceutical Sciences, PharmD Candidate, has found extensive research that these same TZD’s are cardio protective and can serve a valuable role in improving glucose levels in type 2 diabetes patients. This worth reading a couple of times.
Dave Joffe
Editor-in-chief
Newsflash
FDA has approved Farxiga (dapliglozin) to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
TOP STORIES — Diabetes News and Research
Combination dual therapy reduces mortality by 50%.
Obesity and uncontrolled blood glucose have effects on asthma.
Regular lifestyle counseling can have positive long term clinical outcomes in patients with diabetes.
About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.